Combining both biomarkers allows for differentiating human prion diseases from other neurodegenerative processes, and, therefore, the combination of the surrogate markers 14-3-3 and total tau in CSFs is currently the routine analysis for the diagnosis of human prion disease cases. Here, MAPT is linked to prion disease.